Literature DB >> 2512453

Copper histidinate therapy in Menkes' disease: prevention of progressive neurodegeneration.

G Sherwood1, B Sarkar, A S Kortsak.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2512453     DOI： 10.1007/bf03335432

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN： 0141-8955            Impact factor:   4.982


× No keyword cloud information.
  5 in total

1.  Brain tissue accumulates 67copper by two ligand-dependent saturable processes. A high affinity, low capacity and a low affinity, high capacity process.

Authors:  D E Hartter; A Barnea
Journal:  J Biol Chem       Date:  1988-01-15       Impact factor: 5.157

Review 2.  Functions of trace elements in brain metabolism.

Authors:  J R Prohaska
Journal:  Physiol Rev       Date:  1987-07       Impact factor: 37.312

Review 3.  Of mice and men, metals and mutations.

Authors:  D M Danks
Journal:  J Med Genet       Date:  1986-04       Impact factor: 6.318

4.  The failure of parenteral copper therapy in Menkes Kinky Hair syndrome.

Authors:  A D Garnica
Journal:  Eur J Pediatr       Date:  1984-06       Impact factor: 3.183

5.  Congenital dopamine-beta-hydroxylase deficiency. A novel orthostatic syndrome.

Authors:  A J Man in 't Veld; F Boomsma; P Moleman; M A Schalekamp
Journal:  Lancet       Date:  1987-01-24       Impact factor: 79.321
  5 in total
  13 in total

1.  Inhibition of copper absorption by zinc. Effect of histidine.

Authors:  R A Wapnir; C Balkman
Journal:  Biol Trace Elem Res       Date:  1991-06       Impact factor: 3.738

Review 2.  Menkes disease: recent advances and new aspects.

Authors:  Z Tümer; N Horn
Journal:  J Med Genet       Date:  1997-04       Impact factor: 6.318

3.  Screening for Menkes disease using the urine HVA/VMA ratio.

Authors:  M Matsuo; R Tasaki; H Kodama; Y Hamasaki
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

4.  Reversion of hypertrophic cardiomyopathy in a patient with deficiency of the mitochondrial copper binding protein Sco2: is there a potential effect of copper?

Authors:  P Freisinger; R Horvath; C Macmillan; J Peters; M Jaksch
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

5.  Clinical and biochemical consequences of copper-histidine therapy in Menkes disease.

Authors:  J Kreuder; A Otten; H Fuder; Z Tümer; T Tønnesen; N Horn; D Dralle
Journal:  Eur J Pediatr       Date:  1993-10       Impact factor: 3.183

Review 6.  Recent developments in Menkes disease.

Authors:  H Kodama
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

7.  Novel mutations and clinical outcomes of copper-histidine therapy in Menkes disease patients.

Authors:  Ja Hye Kim; Beom Hee Lee; Yoo-Mi Kim; Jin-Ho Choi; Gu-Hwan Kim; Chong Kun Cheon; Han-Wook Yoo
Journal:  Metab Brain Dis       Date:  2014-06-13       Impact factor: 3.584

8.  Neurodevelopment and brain growth in classic Menkes disease is influenced by age and symptomatology at initiation of copper treatment.

Authors:  Stephen G Kaler
Journal:  J Trace Elem Med Biol       Date:  2014-08-28       Impact factor: 3.849

9.  Clinical outcomes in Menkes disease patients with a copper-responsive ATP7A mutation, G727R.

Authors:  Jingrong Tang; Anthony Donsante; Vishal Desai; Nicholas Patronas; Stephen G Kaler
Journal:  Mol Genet Metab       Date:  2008-08-26       Impact factor: 4.797

10.  Neonatal diagnosis and treatment of Menkes disease.

Authors:  Stephen G Kaler; Courtney S Holmes; David S Goldstein; Jingrong Tang; Sarah C Godwin; Anthony Donsante; Clarissa J Liew; Susumu Sato; Nicholas Patronas
Journal:  N Engl J Med       Date:  2008-02-07       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.